C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.
Upcoming Events
-
Sep 28, 2023 - Sep 29, 2023 Complex In Vitro Model: Qualification Framework Public Workshop
-
Oct 11, 2023 - Oct 15, 2023 IDWeek 2023
-
Oct 18, 2023 - Oct 22, 2023 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting
-
Oct 26, 2023 - Oct 27, 2023 C-Path to host its Scientific Breakthrough Summit 2023
-
Nov 1, 2023 - Nov 4, 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Past Events
More Events >>Successes
- COA Qualification from FDA for Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)
- Qualification of drug-induced kidney injury (DIKI) clinical safety biomarker, composite measure
- COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
- C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)
- C-Path’s PKDOC Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD
- C-Path’s PKDOC Secures FDA Qualification for Enrichment Biomarker in ADPKD
- Regulatory Support For Autosomal Dominant Polycystic Kidney Disease Biomarker
- C-Path Opportunities Table
- EMA Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
- FDA and EMA issue first-of-their-kind Letters of Support for two Kidney Biomarkers
News
-
Sep 20, 2023 The CPP Consortium Welcomes Biohaven as its Newest Member
-
Sep 18, 2023 C-Path and EATRIS Join Forces with New Collaboration Agreement
-
Sep 12, 2023 C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource
-
Aug 25, 2023 C-Path’s Romero Appears on The BioCentury Show
-
Aug 25, 2023 C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium
-
Aug 25, 2023 C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials